50 Landmark Papers every Breast Surgeon Should Know

Lynda Wyld is Professor of Surgical Oncology at the University of Sheffield and a Consultant Oncoplastic Surgeon at Doncaster and Bassetlaw Teaching Hospitals. She is the Past President of the British Association of Surgical Oncology (BASO) and Past Chair of the European Society of Surgical Oncology (ESSO) Education Committee and is a Trustee of the Association of Breast Surgery (ABS).Ramsey Cutress is Professor of Breast Surgery at University of Southampton and a Consultant Surgeon at University Hospital Southampton. He is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, Course Director for the ABS Advanced Skills in Breast Disease Management course, Head of the School for Clinical Academic Training at the Wessex Deanery and breast disease subspecialty editor for the Annals of the Royal College of Surgeons of England, demonstrating his interests in research and teaching.Jenna Morgan Jenna is an NIHR Advanced Fellow Breast Surgery at the University of Sheffield and a Consultant Oncoplastic Surgeon at the Jasmine Breast Unit in Doncaster, UK. She is Past Chair of the Mammary Fold Academic Committee of the ABS. She is a clinical academic with an interest in mixed methods research, geriatric oncology and the psychology or ageing in healthcare settings.

• Section One: Epidemiology1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidenceCollaborative Group on Hormonal Factors in Breast Cancer2. Moderate Alcohol Intake and Cancer Incidence in WomenAllen N, Beral V, Cassabone D, Kan SW, Reeves GK, Brown A, Green J on behalf of the Million Women Study CollaboratorsSection Two: Screening and Prevention3. 3. Tamoxifen for Prevention of Breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NASBP P-1)Fisher B, Costantino J, Wickerman D, et al4. 4. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.Tabar L, Fagerberg G, Duffy SW, et al5. 5. The benefits and harms of breast cancer screening: an independent reviewMarmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.Section Three: Diagnostic Imaging6. 6. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening (DMIST)Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C, Jong R, Rebner M7. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)Leach MO, Boggis CRM, Dixon AK, Easton DF, et al8. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trialTurnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, Hanby A, Brown JSection Four: Surgery: Mastectomy versus conservation9. 9. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancerFisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N10. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast Conserving Therapy: A Meta-AnalysisHoussami N, Macaskill P, Marinovich ML, Morrow M11. Ten year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based studyvan Maaren MC, de Munck L, de Back GH, Jobsen J, van Dalen T, Poortmans P, Strobbe LC, Siesling S.Section Five: De-escalation of Axillary Surgery12. 12. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N13.13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.Giuliano AE, Ballman KV, McCall L, et al.14. 14. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.Donker M, van Tienhoven G, Straver ME, et al1515. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical TrialBoughey JC, Suman VJ, Mittendorf EA, et al.Section Six: Oncoplastic Breast Surgery / Breast Reconstruction16. 16. Planning and use of therapeutic mammaplasty-Nottingham approachS J McCulley and R D Macmillan17.17. Oncoplastic breast‐conserving surgery for women with primary breast cancerNanda A, Hu J, Hodgkinson S, Ali S, Rainsbury R, Roy PG.18.18. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort studyPotter et al19.19. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic SurgeryClough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IMSection Seven: Breast cancer genomics and prognostic tools20.20. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsTherese Sørlie, Charles M. Perou, Robert Tibshirani, Turid Aas, Stephanie Geisler, Hilde Johnsen, et al.21.21. Comprehensive molecular portraits of human breast tumoursThe cancer Genome Atlas Network2222. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFatima Cardoso, Laura J. van’t Veer, Jan Bogaerts, et al for the MINDACT investigators23. 23. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPonder)K. Kalinsky, W.E. Barlow, J.R. Gralow, et al24.24. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancerGordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, and Paul DP PharoahSection Eight: Ductal Carcinoma In Situ25 25. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, et al26.26. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the Sloane ProjectShaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, Sawyer ES, Thomas JS, Hanby AM, Pinder SE, Thompson AM27. 27. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD28. 28. A prognostic index for ductal carcinoma in situ of the breast.Silverstein MJ, Poller D, Craig PH, et alSection Nine: Adjuvant Chemotherapy29. 29. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsPeto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., & Pritchard, K30. 30. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. CREATE-XN Masuda, Soo-Jung Lee, S Ohtani, Y-H Im, E-S Lee, I Yokota, K Kuroi, S-A Im, B-W Park, S-B Kim, Y Yanagita, and S Ohno et alSection Ten: Adjuvant Endocrine Therapy31. 31. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)32.32. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor – positive breast cancer: ATLAS, a randomised trialC Davies et al33. 33. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis et al34.34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialATAC Trialist’s GroupSection Eleven: Immunotherapy / Systemic Therapy35. 35. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialCameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al & Herceptin Adjuvant (HERA) Trial Study Team36.36. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast CancerTutt ANJ, Garber JE, Kaufman B, et al37.37. Pembrolizumab for Early Triple-Negative Breast CancerSchmid, P., et al38.38. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancervon Minckwitz, Huang, Mano, et al. for the KATHERINE InvestigatorsSection Twelve: Adjuvant Radiotherapy39.39. Breast-conserving surgery with or without irradiation in early breast cancer (PRIME II).Ian H Kunkler et al40.40. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trialsEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)41.41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.H Bartelink et al42.42. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)43.43. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects; results from a multicentre, non-inferiority, randomised, phase 3 trial.Brunt AM, et alSection Thirteen: Bisphosphonates44.44. Zoledronic acid as adjuvant therapy for breast cancer (does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk, localised breast cancer), the AZURE trialRobert Coleman, David Cameron, David Dodwell, et al on behalf of the AZURE investigators.45.45. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trialEastell, R., Adams, J., Clack, G., Howell, A., Cuzick, J., Mackey, J., Beckmann, M. W., & Coleman, R. E.Section Fourteen: Surgery for Metastatic Disease46. 46. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.Rajendra Badwe, Rohini Hawaldar, Nita Nair, Rucha Kaushik, Vani Parmar, Shabina Siddique, Ashwini Budrukkar, Indraneel Mittra, Sudeep GuptaSection Fifteen: Breast Cancer in Pregnancy / Prophylactic surgery for family history47.47.Treatment of breast cancer during pregnancy: an observational studyLoibl S, Han SN, Minckwitz GV, Bontenbal M, Ring A, Giermek J et al48.48. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman et al 49.49. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer.Hartmann L., Schaid D., Woods J., Crotty T., Myers J., Arnold P.et al50. 50. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study (Arm 1)Rajiv V Dave, Emma Barrett, Jenna Morgan, et al on behalf of the iBRA-NET Localisation Study collaborative

'Laudable goals, and the book amply fulfills them... the book is compact but dense with information, readable, and affordable.' 'The papers are all written by stellar authorities and are truly practice-changing. It will serve as a useful resource and teaching tool'.Score: 94-Carol Scott-Conner, MD, PhD, MBA, MFA